Montreal, Monday, May 16, 2022 – Nearly 200 people attended the Colloque sur la recherche qui soigne: le cancer du sein en point de mire held on Saturday, April 30 in virtual format as well as face-to-face in Montreal and Chicoutimi. An audience made up of people directly or indirectly affected by breast cancer learned about treatments related to this cancer, including those available through clinical research.
Participants had the opportunity to attend high-quality presentations given by internationally renowned researchers who were able to popularize their remarks to make them accessible to all. The main purpose of this event was to promote clinical research in breast cancer, particularly among people living in the different regions of Quebec.
The second edition of this symposium was organized in a hybrid format by the McPeak-Sirois Group for Clinical Research in Breast Cancer in partnership with the Quebec Breast Cancer Foundation and with the support of Gilead, Merck, Pfizer, AstraZeneca and Oncopole.
“With this symposium, which we wish to hold on an annual basis, we are trying to raise awareness of the importance of clinical research among the general public and to give the member hospitals of our Group the opportunity to highlight their initiatives and teams” emphasizes Dominique Johnson, Managing Director of the Group.
In order to allow the content to be viewed by as many people as possible, the symposium was recorded and the presentations are available on the McPeak-Sirois Group website (in French only).
How to participate in a clinical trial in breast cancer:
Anyone who is interested must first inquire with their attending physician and mention that they wish to participate in a clinical trial. Several study selection criteria must be met in order to participate in such trials and only a doctor can validate them. He will then be able to refer the patient to a doctor who is involved in clinical trials. Patients can also contact directly one of the hospitals that is part of the McPeak-Sirois Group.